Novacyt (LSE:NCYT) FFO


LSE:NCYT Novacyt SA LSE:NCYT
38 GF Score
Price £0.35
GF Value £0.57
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Novacyt FFO?

FFO (Funds from operations) only applies to REITs.

LSE:NCYT
38GF Score
Novacyt SA LSE:NCYT
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Novacyt (LSE:NCYT) Overvalued in 2026?

Based on GuruFocus' analysis, Novacyt stock appears to be undervalued. The current stock price of £0.35 is trading 39.5% below its estimated GF Value™ of £0.57. GuruFocus considers Novacyt to be Possible Value Trap.

Key valuation signals for LSE:NCYT:

  • FFO:
  • GF Value™: £0.57 vs. price of £0.35 (39.5% below fair value)
  • GF Score™: 38/100 with 4 warning signs

No single metric tells the full story. See the LSE:NCYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novacyt Business Description

Address 131 Boulevard Carnot, Le Vesinet, FRA, 78110
Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. The company operates its business through the following business segments: Primer Design, Yourgene Health and Corporate. Majority of the revenue is generated from Yourgene Health segment. Geographically, the company operates in United Kingdom, France, Europe, America, Asia-Pacific, Middle East and Africa generating majority from Asia- pacific region.
38GF Score

Get the complete analysis for LSE:NCYT

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.35
Price
£0.57
GF Value